Celcuity (CELC) Cash from Financing Activities (2016 - 2025)
Celcuity (CELC) reported Cash from Financing Activities of $24.4 million for Q4 2025, up 19770.73% on a YoY basis from N/an in Q4 2024, and down 92.6% quarter-over-quarter from $330.3 million in Q3 2025.
Celcuity (CELC) Cash from Financing Activities (2016 - 2025) Analysis & Trends
Celcuity has reported Cash from Financing Activities for 10 years, with the latest figure at $24.4 million in Q4 2025.
- For the quarter ending Q4 2025, Cash from Financing Activities rose 19770.73% year-over-year to $24.4 million; the trailing twelve-month figure through Dec 2025 stood at $360.6 million (up 160.54% YoY), and the FY2025 full-year result was $360.6 million, up 160.54% from the prior year.
- Cash from Financing Activities for Q4 2025 stood at $24.4 million, down from $330.3 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $330.3 million in Q3 2025, with the low at -$108166.0 in Q3 2022.
- Historically, Cash from Financing Activities has averaged $38.9 million across 5 years, with a median of $3.2 million in 2024.
- Annual changes were most pronounced in 2021 — Cash from Financing Activities surged 1797799.65% — and 2022, when it plunged 100.51%.
- Celcuity's Cash from Financing Activities stood at $53510.0 in 2021, then jumped by 225188.94% to $120.6 million in 2022, then slumped by 46.37% to $64.7 million in 2023, then slumped by 99.81% to $123000.0 in 2024, then surged by 19770.73% to $24.4 million in 2025.
- The last three Cash from Financing Activities figures came in at $24.4 million (Q4 2025), $330.3 million (Q3 2025), and $232000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 53,000.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 85,464.43 |
| 10 | Celcuity | 4.14 Bn | 3.42 Bn | - | 24.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 24.44 Mn |
| Dec 31, 2025 | 24.44 Mn |
| Sep 30, 2025 | 330.33 Mn |
| Sep 30, 2025 | 330.33 Mn |
| Jun 30, 2025 | 232,000.00 |
| Jun 30, 2025 | 232,000.00 |
| Mar 31, 2025 | 5.55 Mn |
| Mar 31, 2025 | 5.55 Mn |
| Dec 31, 2024 | 123,000.00 |
| Dec 31, 2024 | 123,000.00 |
| Sep 30, 2024 | 803,000.00 |
| Sep 30, 2024 | 803,000.00 |
| Jun 30, 2024 | 123.38 Mn |
| Jun 30, 2024 | 123.38 Mn |
| Mar 31, 2024 | 14.08 Mn |
| Mar 31, 2024 | 14.08 Mn |
| Dec 31, 2023 | 64.66 Mn |
| Dec 31, 2023 | 64.66 Mn |
| Sep 30, 2023 | 15,244.00 |
| Sep 30, 2023 | 15,244.00 |